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Abstract 
A new paradigm in metallobiochemistry describes the activation of inactive metalloenzymes by 
metal ion removal. Protein tyrosine phosphatases (PTPs) do not seem to require a metal ion for 
enzymatic activity. However, both metal cations and metal anions modulate their enzymatic activity. 
One binding site is the phosphate binding site at the catalytic cysteine residue. Oxyanions with 
structural similarity to phosphate, such as vanadate, inhibit the enzyme with nanomolar to 
micromolar affinities. In addition, zinc ions (Zn2+) inhibit with picomolar to nanomolar affinities. We 
mapped the cation binding site close to the anion binding site and established a specific mechanism 
of inhibition occurring only in the closed conformation of the enzyme when the catalytic cysteine is 
phosphorylated and the catalytic aspartate moves into the active site. We discuss this dual inhibition 
by anions and cations here for PTP1B, the most thoroughly investigated protein tyrosine 
phosphatase. The significance of the inhibition in phosphorylation signaling is becoming apparent 
only from the functions of PTP1B in the biological context of metal cations as cellular signaling ions. 
Zinc ion signals complement redox signals but provide a different type of control and longer lasting 
inhibition on a biological time scale owing to the specificity and affinity of zinc ions for coordination 
environments. Inhibitor design for PTP1B and other PTPs is a major area of research activity and 
interest owing to their prominent roles in metabolic regulation in health and disease, in particular 
cancer and diabetes. Our results explain the apparent dichotomy of both cations (Zn2+) and 
oxyanions such as vanadate inhibiting PTP1B and having insulin-enhancing (“anti-diabetic”) effects 
and suggest different approaches, namely targeting PTPs in the cell by affecting their physiological 
modulators and considering a metallodrug approach that builds on the knowledge of the insulin-
enhancing effects of both zinc and vanadium compounds. 
1. Introduction 
Over sixty years ago, the late Bert L. Vallee suggested that “[metal ions] may accelerate or inhibit 
reactions selectively. With reference to the latter, one can point out that about 50 per cent of all 
known enzymes require free sulphhydryl groups for activity: it is well known that metal ions can 
react with sulphhydryl groups, thereby inhibiting these enzymes. It is completely unknown whether 
the body avails itself for inhibiting, activating, or both actions of metal – or neither – to control 
enzyme reactions” [1]. Even today, it remains largely unknown to which extent the transition metal 
ions and zinc control enzymatic reactions. Clearly, metal ions activate apoenzymes to form active 
holoenzymes, i.e. metalloenzymes, but this aspect of metallobiochemistry is not considered part of 
regulation. It is estimated that about 50% of all enzymes require a metal ion, and it is assumed that 
metalloenzymes are 100% metallated and that the metal ion remains bound during the lifetime of 
the protein. However, a paradigm for the opposite situation is emerging, namely an active 
apoenzyme without a metal ion and an inactive holoenzyme with a bound metal ion [2]. This is 
borne out by the observation of different types of enzymes with diads or triads of potentially metal 
ion-coordinating catalytic groups in the active site being very tightly inhibited by zinc ions [3, 4]. This 
inhibition suggests metallation states different from 100% occupancy, and modulation of enzyme 
activities by fluctuating metal ion concentrations. In this article, we will discuss protein tyrosine 
phosphatases (PTPs) as metal-modulated enzymes. In contrast to other phosphatases, many of 
which are active metalloenzymes, PTPs are generally not recognized as metalloenzymes but bind 
metal cations such as Zn2+ and metal anions such as vanadate extremely tightly and with 
concomitant inhibition. The fact that zinc ion concentrations in the cell are in the range where such 
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enzyme inhibition is observed strongly supports the idea that zinc(II) modulates protein tyrosine 
phosphatase activity in vivo [2]. Physiological metal ion modulation is different from metal ion 
inhibition of PTPs as a mechanism of toxicity or exploration of metal ligand complexes for 
pharmacological regulation. 
Zinc(II) is now known to be a cellular signaling ion, but targets have not been confirmed. PTPs are 
likely targets as phosphorylation states of many signaling proteins depend on changes in cellular 
zinc(II). It appears that we have missed a major area of metabolic regulation, in particular a role of 
zinc ions in the most significant way of signal transduction, namely phosphorylation signaling, and 
that the number of enzymes that interact with zinc(II) is significantly larger than the already 
impressive estimate that about 3000 human proteins may require zinc(II) as a cofactor [5]. 
 
1.1 Protein Tyrosine Phosphatases (PTPs) 
Protein tyrosine phosphorylation is a dynamic process that regulates many cellular processes 
through the activities of kinases and phosphatases. Dysregulation of either one of these enzymes is 
linked to multiple diseases. The human genome contains 107 PTPs divided into several subgroups 
[6]. The cysteine-based PTPs constitute the largest group, which includes the dual-specificity and 
classical tyrosine-only transmembrane, receptor-like PTPs (RT-PTP) and non-transmembrane PTPs 
[7]. Amongst the classical non-transmembrane PTPs is PTP1B (PTPN1), with a catalytic N-terminal 
domain, a regulatory region, and a membrane-localization domain that tethers the enzyme to the 
cytosolic side of the endoplasmic reticulum (ER) [8].  
PTP1B dephosphorylates several substrates including the insulin and leptin receptors, hence having 
an important role in metabolism. PTP1B knock-out (KO) mice are more sensitive to insulin and have 
lower serum glucose and insulin levels; when put on a high fat diet, they are resistant to weight gain 
and insulin. Moreover, the phosphorylation of the insulin receptor (IR) in both skeletal muscle and 
liver is increased in KO compared to control mice [9]. Transgenic mice overexpressing PTP1B 
specifically in the muscles show impaired insulin sensitivity [10]. Although mutations of the PTP1B 
gene have not been linked to cancer and despite the fact that PTP1B regulates the activity of both 
the epidermal growth factor (EGF) and the platelet-derived growth factor (PDGF) receptors [11], the 
enzyme is considered a tumor suppressor. Overexpression of PTP1B in fibroblasts protects the cells 
from transformation [12], and increased PTP1B expression is observed in breast and ovarian cancer 
patients, possibly in response to increased levels of tyrosine phosphorylation [13, 14]. However, the 
actual role or modulation of PTP1B in cancer treatment or prevention is still under debate. Owing to 
these critical cellular functions, PTP1B has been the subject of numerous investigations.  
PTP activity is tightly regulated by a plethora of mechanisms including oxidation, phosphorylation, 
sumoylation, and dimerization [15-19]. In recent years, evidence accumulated that metal ions may 
also regulate PTP activity. Here we review metal ion regulation of PTPs and address its coordination 
chemistry and significance, with a focus on PTP1B. 
 
1.2 The PTP1B-catalyzed reaction 
PTP1B is the prototype of protein tyrosine phosphatases, originally isolated from placenta [20]. The 
catalytic domain of PTP1B consists of 280 residues. The enzymatic mechanism responsible for the 
dephosphorylation of phosphorylated substrates involves engagement of the phospho-tyrosine 
  
5 
 
substrate to PTP1B and promotion of a conformational change of the so-called WPD loop that moves 
closer to the phospho-tyrosine and allows the side chain of Asp181 to act as a general acid/base. The 
side chain of Arg221 changes orientation and assists the closure of the WPD loop. Interactions 
between the re-positioned Arg221, which stabilizes the phosphate group, and the Trp179 and Pro180 
residues stabilize the WDP loop in the closed conformation. The sulphhydryl group of Cys215 is the 
catalytic residue. It has a characteristically low pKa of 5.5 [21] and performs a nucleophilic attack on 
the phosphate group of the phospho-tyrosine substrate while Asp181 transfers a proton to the 
tyrosine oxygen group of the leaving substrate. In the second step, the resulting phospho-cysteine 
intermediate is hydrolyzed. Gln262 aligns a water molecule for the nucleophilic attack on the 
phospho-cysteine intermediate while Asp181 now functions as a general base accepting a proton (Fig. 
1). Asp181 is thought to have a very high pKa of 6.8 [22]; it moves 8 Å when the WPD loop closes and 
is thought to be protonated in the closed conformation [22]. The removal of the phosphate from the 
catalytic cysteine leads to the re-opening of the WPD loop, terminating the catalytic cycle [23, 24]. 
[FIGURE 1] 
 
1.3 Measuring enzymatic activity in the presence of metal ions 
PTP activity is measured with several enzymatic assays; most of them involve the use of a small 
molecule or a peptide. Dephosphorylation of these substrates can be detected by fluorescence (e.g., 
6,8-Difluoro-4-Methylumbelliferyl Phosphate, DiFMUP), electronic absorption (e.g., p-nitrophenyl 
phosphate, pNPP) or radioactivity (e.g., 32P-labelled phospho-peptides) [25]. Many published 
experiments are based on an end-point assay. Quenching the reaction at a given time point and 
calculating the amount of product formed does not provide evidence for linear rates and thus 
important characteristics of the enzymes are missed. Therefore, determining the activity under 
steady-state conditions with initial rates is superior for mechanistic investigations.  If metal ion 
binding is competitive with substrate binding, then IC50 values relative to the substrate 
concentration employed in the assays are obtained. The true Ki values can be significantly lower. For 
example, an IC50 value of 98 pM was estimated for receptor protein tyrosine phosphatase β (PTPRB), 
but the Ki value is actually 21 pM after a full kinetic analysis was performed [26]. 
When measuring the activity of enzymes in the presence of metal ions, their concentrations are 
rarely controlled. If inhibition by metal ions occurs at very low concentrations, spurious amounts of 
metal ions are already present as contaminants in control reactions in the absence of any added 
metal ions, even when the chemicals in all solutions are certified by commercial metal analysis. 
Hence, additional metal analyses and the use of a metal ion buffer to control metal ion 
concentrations may be necessary for analyzing inhibition. Another issue is that typical assay 
conditions for PTPs involve additional agents that participate in metal ion buffering; their metal ion 
binding capacity must be considered. The origin of the protein is also important. Most PTPs used in 
research are recombinant: they are produced by individual investigators or bought from companies 
that focus on the preparation of active enzymes. The proteins usually contain EDTA, glutathione 
(GSH), dithiothreitrol (DTT), or other metal ion chelating agents that compete with the protein for 
metal ion binding. The presence of these agents will influence the free metal ion concentrations. 
Therefore, when assays are performed in the absence of a metal ion buffer, the reported inhibition 
constants may need to be re-evaluated as the inhibition is likely to be stronger.  
In our experiments, we employ metal ion buffers that control the free metal ion concentrations. The 
choice of the chelating agent as a metal ion buffer depends on the desired buffering range, and for 
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the measurement of PTPs it is nitrilotriacetic acid (NTA), as it buffers metal ions such as Zn(II), Cd(II) 
and Cu(II) in the range where inhibition is observed. Moreover, we measure the total amount of 
metal present in the solutions by ICP-MS. Using software such as MaxChelator [27] or MINEQL+ 4.6 
(Environmental Research Software, Hallowell, ME), we then calculate the free metal ion 
concentration from the overall composition of the buffer, including the concentration of metal ion 
chelators present in the solution of the protein, and the measured and added concentrations of 
metal ions [28]. In this way we obtain the free metal ion concentrations for each of the total metal 
ion concentrations added (Table 1). The differences found when comparing the output from the two 
software packages is probably due to the different algorithms used and the fact that, while 
MaxChelator calculates free metal ion concentrations using only the total metal ion and chelator 
concentrations, MINEQL+ also takes into account other buffer components. The free metal ion 
concentrations are significantly different from the total metal ion concentrations. In fact, this metal 
ion buffering in vitro is not any different from the situation in vivo, where all metal ions are buffered 
in specific ranges by proteins and small molecules. 
 
Table 1. Free zinc ion concentrations calculated using MaxChelator and MINEQL+ 4.6 software and compared to the total 
zinc ion concentration. The buffer composition (50 mM Hepes/Na+, 0.1 mM tris-carboxyethylphosphine (TCEP), and 1 mM 
nitrilotriacetic acid (NTA)), pH (7.4), temperature (25 °C), and ionic strength were taken into account to calculate the free 
zinc ion concentrations [28].  
 
Zn
2+
 (Tot) (µM) 
[Zn
2+
]free (M) 
MaxChelator 
[Zn
2+
]free (M) 
MINEQL+ 
10  2.66 × 10-11 2.93 × 10-11 
30 8.14 × 10-11 8.98 × 10-11 
100 2.93 × 10-10 3.22 × 10-10 
300  1.13 × 10-9 1.24 × 10-9 
500  2.63 × 10-9 2.9 × 10-9 
600  3.95 × 10-9 4.34 × 10-9 
700  6.15 × 10-9 6.72 × 10-9 
800  1.05 × 10-8 1.14 × 10-8 
900  2.37 × 10-8 2.45 × 10-8 
950  5.01 × 10-8 4.45 × 10-8 
990  2.56 × 10-7 8.87 × 10-8 
1000  1.70 × 10-6 1.06 × 10-7 
 
2. Metal Ion Coordination in PTP1B 
Metal ions bind to proteins through interaction with the donors of amino acid side chains, the 
ligands. The cellular concentrations of the different metal ions vary substantially, and for some metal 
ions participating in cell signaling, the concentrations fluctuate and depend on the status of the cell.  
The coordination number is governed by the properties of both the metal ions (e.g., charges, size) 
and the ligands (e.g., electronegativity). Coordination numbers have been analyzed by employing the 
Cambridge Structural Database [29]. Although most metal ions have preferences towards a 
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particular coordination number, they can assume different geometries and have more than one 
coordination number. Moreover, metal ions have ligand preferences (Table 2).  
 
Table 2. Amino acids in the metal ion-binding sites of proteins. Frequencies of each amino acid in a given type of metal 
ion–binding site are tabulated; where not shown the frequency is below 4%. Metal ion–binding polypeptides were 
extracted from the RCSB Protein Data Bank (PDB).  
 
Amino 
Acid 
Metal ion 
Ca
2+
 Cd
2+
 Cu
2+
 Fe
3+
 Mg
2+
 Mn
2+
 Zn
2+
 
Arg - - - - - - - 
Asn 10-15%a - - - 5-10%a ~5%a - 
Asp 
35-40%a 
36%b 
24%b ~5%a 10-15%a 
35-40%a 
35%b 
40-45%a 
37%b 
10-15%a 
17%b 
Cys - 10%b 10-15%a 10-15%a - - 
40-45%a 
23%b 
Glu 
15-20%a 
27%b 
27%b ~5%a - 
15-20%a 
22%b 
15-20%a 
25%b 
10-15%a 
15%b 
Gln - - - - - - - 
Gly 5-10%a - - - - - - 
His - 26%b 65-70%a 45-50%a ~5%a 
20-25%a 
26%b 
30-35%a 
36%b 
Met - - 5-10%a - - - - 
Ser ~5%a - - - 5-10%a - - 
Thr ~5%a - - - 5-10%a - - 
Tyr - - ~5%a 5-10%a - - - 
 
aMetal ion-binding sites were defined as residues within 3.5 Å of the metal ion [30]. bMetal ion-binding sites were defined 
as residues within 2.5 Å of the metal ion [31]. 
 
Although the tabulation shows that arginine and glutamine side chains are not typical ligands for zinc 
ions and other metal ions, there are at least 20 established cases where proteins coordinate zinc 
ions with glutamine [32].  
 
2.1 Metal ion binding to PTP1B 
The enzymatic activity of PTPs is affected by both metal cations and (metal) oxyanions. Among 
those, zinc ions (Zn2+) and vanadate ions (VO4
3-) were originally described as inhibitors of PTP1B [20]. 
 
2.2 Metal cations inhibit PTPs 
We interrogated the Protein Data Bank (PDB) for metal cations (Cd(II), Cu(II), Zn(II), Fe(II)) bound to 
human PTP1B. None of the 129 crystal structures deposited contains any of these metal ions near 
the catalytic site. This finding, however, does not mean that metal ions are unable to bind to PTP1B.  
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2.2.1 Zinc(II) 
Zinc(II) has been known as an inhibitor of PTPs since the early 1980s [33]. Since then, others 
confirmed inhibition and reported increasingly higher IC50 or Ki values [28, 34]. What is often 
overlooked, however, is that, compared to other metal ions such as cadmium(II) or copper(II), the 
inhibition of PTPs by zinc(II) occurs at biologically relevant metal ion concentrations. PTP1B is not the 
only protein tyrosine phosphatase inhibited by zinc ions. Other PTPs are also inhibited (Table 3).  
Zinc ions also inhibit PTPs in cultured cells. When glioma cells were incubated with zinc ion 
concentrations in the presence of the zinc(II) ionophore pyrithione, a time-dependent increase in 
protein tyrosine phosphorylation was observed [34, 35]. Zinc ions also activate the epidermal growth 
factor receptor (EGFR) in human bronchial epithelial cells. Although the activation fails to trigger the 
dimerization of EGFR typically induced by EGF, it increases phosphorylation, which is accompanied 
by a loss of PTP activity. In particular, zinc ions caused an inhibition of PTP1B, suggesting that the 
mechanism responsible for zinc ion-induced activation of EGFR signaling is dependent on the 
inhibition of PTP1B by zinc ions [36-38]. 
 
Table 3. Zinc(II) inhibition of human protein tyrosine phosphatases. 
Protein Tyrosine 
Phosphatase 
Inhibition Reference 
PTP1B IC50 = 3-17 nM [28, 34] 
SHP-1 IC50  = 93 nM [35] 
SHP-2 IC50 = 1-2 μM [34] 
LAR (PTPRF) IC50  = 20 μM [34] 
TC-PTP IC50 = 200 nM [4] 
PTPRB IC50 = 98 pM; 
Ki = 21 pM 
[26] 
PTEN IC50 = 0.6 nM [39] 
 
When we examined the inhibition of PTP1B by zinc ions, we observed that the enzyme remained at 
least 50% active even in the presence of high zinc ion concentrations. This observation is not unique 
to PTP1B. Both PTPRG and HePTP behave in similar ways (M. Wilson, unpublished data). Because the 
dephosphorylated substrate is released in the first catalytic step, the retention of 50% activity 
suggests that the enzyme is inhibited in the second catalytic step when it is still in the 
phosphorylated form. This observation would indeed explain the failure to see complete inhibition 
even at high zinc ion concentrations [28]. We have recently investigated the possible binding sites of 
zinc(II) to PTP1B with molecular docking [28]. Since the enzyme undergoes conformational changes 
during the catalytic cycle, we investigated zinc(II) binding to three different conformations of the 
protein: the enzyme in the open conformation (PDB id: 2CM2), the enzyme in the closed 
conformation with the phospho-cysteine intermediate (PDB id: 1A5Y) and the dephosphorylated 
enzyme in the closed conformation, which was obtained by removing vanadate from the second 
transition state structure (PDB id: 3I80). For each of the structures, we found several zinc ion-binding 
sites at the periphery of the enzyme (Table 4, [28]).  
 
Table 4. Potential zinc ion-coordinating ligands in three structures of PTP1B as obtained from molecular docking [28].   
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PDB id Pose 1
a
 Pose 2 Pose 3 Pose 4 Pose 5 
2CM2 
Lys141 
Thr143 
Glu159 
Glu161 
Glu2 
Glu4 
Glu6 
Glu4 
Lys5 
Glu8 
His0 
His1 
Glu2 
Asp240 
Asp29 
Pro31 
Cys32 
Met258 
3I80 
Lys141 
Thr143 
Glu159 
Glu161 
Glu2 
Met3 
Glu4 
Ile275 
Ala278 
Glu8 
Asp11 
Asp181 
Cys215 
Arg221 
Gln262 
Asp289 
Lys292 
Glu293 
1A5Y 
Met74 
Glu75 
Glu76 
Asp252 
His60 
Glu101 
Asp181 
P-Cys215 
Gln266 
His25 
Glu26 
Glu129 
Glu132 
 
  
aCandidate binding modes are referred to as “poses” in molecular docking. 
 
Remarkably, zinc ion binding to the catalytic site was observed only when the conformational 
change of the WPD loop has occurred and the catalytic residue Asp181 has moved into the active site 
(PDB id: 1A5Y, pose 3 and PDB id: 3I80, pose 4). In the dephosphorylated form of the enzyme 
(obtained by removing vanadate from the structure), zinc(II) is in a coordination sphere surrounded 
by Asp181, Arg221, Gln262 and Cys215 (Fig. 2A). In the phospho-intermediate form, phospho-Cys215, 
Asp181 and Gln266 and Gln262 are all in the inner coordination sphere of zinc(II) (Fig. 2B). The crystal 
structure of this form examined has a Gn262Ala mutation, hence Gln262 coordination of zinc(II) is not 
shown in Fig. 2B but it has a critical position for coordination (Fig. 2A). If Gln262 is re-introduced in 
the position in silico, the coordination of the docked zinc ion is very strong with a distance of about 
1.5 Å. If Tyr46 changes its position, it may become a ligand as well. The open conformation fails to 
accommodate zinc(II) in the catalytic pocket. The idea that zinc(II) binds to the catalytic site is 
supported by the observations that zinc(II) is a competitive inhibitor of PTPRB [26]. When comparing 
the two binding modes (Fig. 2A, B), the center of the zinc ion moves at least 4 Å. The inhibitory 
effect of zinc(II) is expected to be two-fold. When Gln262 and Asp181 become ligands of zinc(II) in the 
closed conformation, Gln262 no longer aligns a water molecule for catalysis and Asp181 can no longer 
serve as the catalytic base for the dephosphorylation of the phospho-cysteine intermediate in the 
second step of the reaction. Hence zinc(II) traps the enzyme in the phospho-cysteine form. The 
coordination of zinc(II) in this form is exclusively from oxygen donors.  
[FIGURE 2] 
Though the zinc(II) site in the closed conformation of PTP1B is unlike typical zinc(II) coordination in 
zinc metalloenzymes, it is not without precedence.  The number of oxygen donors is sufficient to 
provide a strong binding site as zinc(II) binds to the magnesium(II) site in phosphoglucomutase and 
inhibits the enzyme with picomolar affinity [40]. In PTP1B, Gln266 (1 oxygen), Asp181 (1-2), phosphate 
(1-2), and Gln262 (1) could all contribute oxygen ligands.  Gln has been identified as a ligand of zinc(II) 
in proteins [32]. Alternatively, or additionally, water molecules may be ligands. Hydrogen bonding of 
metal ion-bound water molecules also makes an energetic contribution to the stability of metal ion 
sites in proteins. The implication of zinc(II) locking the enzyme in the phosphorylated state is that the 
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site is now no longer accessible for substrate. We believe that zinc(II) binding in the active site in the 
closed conformation in the absence of phosphate (Fig. 2A) is not relevant as the closed 
conformation would require the prior presence of substrate, e.g. the phosphorylated insulin 
receptor. Zinc(II) would not be an insulin-mimetic as the insulin receptor would not function in 
signaling if PTP were to remain bound to it.  We cannot rule out, however, that zinc(II) locks the 
enzyme in a closed conformation once the second substrate, i.e. the phosphate group, has left the 
catalytic site. At present, there does not seem to be a precedent for this mechanism as the cleavage 
of the phospho-cysteine intermediate is coupled to the transition of the enzyme from the closed to 
the open conformation.     
2.2.2 Iron(II) 
Mononuclear di-citrate (cit) iron complexes interact with PTPs and inhibit their activities [41]. 
Specifically, while Fe:cit prepared with Fe(III) in 1:1 and 1:2 ratios did not inhibit tyrosine 
phosphatases, inhibition was observed for the 1:4 and the 1:10 Fe:cit preparations (at 
concentrations between 250 and 500 μM of the complex) [41]. Fe2+ inactivates recombinant PTPs 
(PTP1B, CD45, and LAR) in a concentration-dependent manner [42]. Since reactive oxygen species 
are implicated in regulating PTP1B activity, and iron(II) is involved in the Fenton reaction 
(decomposing H2O2), the interaction of H2O2 and Fe
2+ with PTP1B was also examined. Physiological 
concentrations of Fe2+ (~500 nM, [43]) not only inactivated the enzyme less than H2O2 but also 
prevented its inactivation by H2O2, possibly by generating hydroxyl radicals which, although 
oxidizing, are unspecific reactants likely unable to reach the catalytic site of PTPs because they 
would not diffuse that far in vivo. Fe2+ also inhibits the dual specificity protein phosphatase VHR and 
the inhibition was reversible by addition of EDTA, suggesting a direct binding of iron(II) to this PTP 
[44].  
2.2.3 Copper(II) 
Inhibition of PTPs has been explored with copper(II) complexes. The inhibition constants vary 
between low nM to low µM values [45-48]. The effect of the free metal ion, though unbuffered, was 
also examined for both PTP1B and the dual specificity protein phosphatase VHR. Copper(II) strongly 
inhibited with IC50 values of 100 nM and 1 µM for VHR and PTP1B, respectively. However, enzymatic 
activity was not fully recovered by adding EDTA. Only the presence of reducing agents reactivated 
the enzymes completely, suggesting that copper(II) oxidizes the catalytic cysteine [44]. Considering 
the very low free cytosolic copper ion concentrations and the fact that intracellular copper is mostly 
in the reduced state (copper(I)), these experiments are not physiologically significant. When 
investigating PTP1B in the presence of increasing concentrations of Cu2+ and a metal buffering 
system, we found a much lower IC50 value of 0.3 pM (unpublished data, K. Birla Singh).  
2.2.4 Cadmium(II) 
Although Cd2+ inhibits other phosphatases, there is no report on its effect on PTPs [49]. When PTP1B 
was investigated in the presence of increasing concentrations of Cd2+ in an NTA-containing buffer, an 
apparent inhibition constant of  ≈5 nM was obtained (unpublished data, K. Birla Singh), very similar 
to the one for zinc(II) (5.6 nM), based on concentrations of free cadmium ions calculated as 
indicated above for zinc. 
 
  
11 
 
2.3 Oxyanions inhibit PTP activity  
Inorganic phosphate is the hydrolytic product of the PTP reaction. It is  a competitive inhibitor of 
PTP1B with a Ki value of ~ 17 mM [50]. Other oxyanions with structural similarities to the phosphate 
group inhibit PTPs with different affinities: molybdate, arsenate [50], tungstate and vanadate. When 
analyzing the inhibition of PTP1B under our experimental conditions, apparent Ki (IC50) values of 1.5 
μM (vanadate), 9 μM (heptamolybdate), 210 μM (tungstate), 200 μM (arsenate), and 54 mM 
(nitrate) were measured (unpublished data, K. Birla Singh). The different inhibition constants may 
reflect the different ionization states of the anion at the pH of investigation, the propensity of 
vanadate to form a covalent intermediate analogous to the phospho-intermediate in contrast to the 
other anions, which form Michaelis-like complexes, and geometric factors, such as in the case of 
nitrate, which has a planar geometry (Table 5). 
 
Table 5. Oxyanions in biological systems. 
 
Name of Ion Formulaa Chargea PDB 
code # entries Geometry
b,c
 
Arsenate  HAsO42- -2 ART 3 TH 
Chromate  H2CrO4- -1 - 0 - 
Molybdate MoO42- -2 MOO 22 TH, TB 
Phosphate HPO42- -2 PO4 4156 TH 
Sulphate  SO42- -2 SO4 14234 TH, TB 
Tungstate  WO42- -2 WO4 48 TH, TB 
Vanadate H2VO4- -1 VO4 80 TH, TB 
   
aObserved under standard condition of temperature (25 °C) and pH (7.4). bTH – tetrahedral; 
TB – trigonal bipyramidal. cFrom the Protein Data Bank (PDB). 
 
2.3.1 Vanadate(V) and oxidovanadium(IV)  
The bioinorganic coordination chemistry of vanadium is discussed in a number of very recent 
reviews, covering vanadate in structural biology [51], the reaction dynamics of vanadium ions [52], 
binding, transport, and storage of vanadium in cells [53], vanadium in medicine [54, 55], and 
vanadium as inhibitors of phosphatases [56]. Vanadate has structural similarities with phosphate, 
and was therefore suggested to be a transition state analogue of phosphate in phosphatases [57]. 
However, the two anions differ significantly in their acid/base and redox chemistries. The pKa2 values 
are 7.8 for dihydrogen vanadate (H2VO4
-) and 7.2 for dihydrogen phosphate. Thus there is 
comparatively less di-anion (HVO4
2-) at pH 7.0. Only the oxidation state +5 of the non-metal 
phosphorous is relevant for mammalian biology, whereas minimally two oxidation states of the 
metal vanadium, +4 and +5, are important.  Thus phosphorous is redox-inert whereas vanadium is 
redox-active in biology. Vanadate was discovered as a strong inhibitor of (Na,K)-ATPase in a 
commercial ATP preparation (Ki = 40 nM in the presence of 25 mM Mg
2+) [58]. It is a competitive 
inhibitor of PTP1B with a Ki of 0.38 ± 0.02 μM (pH 7.3) [59]. In contrast to other oxyanions such as 
sulphate, vanadate, like phosphate, forms a covalent intermediate with the enzyme. Vanadate 
inhibits bovine low molecular weight PTP competitively with a Ki of 1.0 ± 0.6 μM (pH 7.5) and forms a 
trigonal bipyramidal (tbp) SN2 transition state [60]. While a square planar geometry of the 5-
coordinate complexes of vanadate is preferred in solution, the geometry of intermediates is tbp in a 
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large number of phosphatases [56, 61]. Analysis of geometry was based on angular parameters using 
τ-values, the ratio of the angle of the axial vs the equatorial ligands in tbp geometry divided by 60, 
i.e., τ = (β-α)/60, which, for an ideal geometry with β = 180o and α = 60o, gives a τ-value of 1 [62]. In 
the covalent intermediate of PTP1B, the sulphur donor of the catalytic cysteine becomes the fifth 
ligand of vanadium(V) with a rather long bond distance (2.4 to 2.5 Å in the two transition states) and 
deviations from the ideal tbp transition state of vanadium(V) with τ-values ranging from 0.83 (PDB id 
3I7Z) to 0.90 (PDB id 3I80) and structures described best as umbrella-like inversions with deviations 
of ligands from the equatorial plane in exploded transition states, a term referring to increased bond 
lengths of the breaking and forming bonds. Further investigations employing shape analysis - 
continuous symmetry measures [63] - demonstrated that the umbrella-like distortions of the tpb 
species are on a pathway from and to the tetrahedral anions [64]. These characteristics make 
vanadate a transition state analogue for PTPs [65]. Vanadate and other oxyanions that form product 
complexes like phosphate have been used for 3D-structural elucidation of the enzymatic mechanism 
of PTP1B. The structures of two transition states of PTP1B with vanadate ions were analyzed 
crystallographically [24]. The structures share close structural characteristics with the 
metaphosphate and orthophosphate transition states in phosphate transfer reactions [65]. The first 
transition state was obtained by crystallizing PTP1B in the presence of metavanadate and a peptide, 
while the second transition state was obtained by incubating PTP1B crystals with the peptide and 
orthovanadate. In both transition states, vanadate binds to the sulphur of Cys215; the equatorial 
oxygen atoms bind to the amide groups of the P-loop (Ser216, Ala217, Gly218 and Ile219) and to the 
guanidinium group of Arg221. Gln262 in the first transition state is rotated compared to the position in 
the second transition state, where it binds the apical oxygen in the trigonal vanadate moiety [24] 
(Fig. 3A, B). The motion of Gln262 is critically important as it aligns a water molecule as a nucleophile 
for releasing the second product, phosphate, from the intermediate. Together the structures of 
complexes with different oxyanions, i.e., phosphate, vanadate, and tungstate were instrumental in 
formulating the reaction pathway of PTP1B (Fig. 1). 
[FIGURE 3] 
Pervanadate, which contains monoperoxo or diperoxo ligand bridges in the equatorial position, also 
inhibits PTPs and is a more potent insulin-mimetic than vanadate [66]. However, the mechanism of 
inhibition is different from vanadate. Pervanadate is an irreversible inhibitor of PTPs. Mass 
spectrometric analyses revealed that addition of pervanadate to the enzyme resulted in the 
oxidation of the catalytic cysteine to a sulphonic acid derivative [59].  
Crystals of the Yersinia enterocolitica PTP YopH, in which the Trp in the WPD loop had been mutated 
to a Phe, grown in the presence of vanadate, showed electron density that was interpreted as a 
divanadate (V2O7
x-) ion bound in the active site [67]. This particular species of vanadate has never 
been observed in wild type Yersinia PTP or in any other PTP. A 2.2 Å structure with vanadate is 
deposited in the PDB (id 2I42) and is discussed as having a mononuclear VO4S covalent intermediate 
[56]. Although vanadate forms oligomers in solution, wild type, active PTPs are expected to catalyze 
the decomposition of dimeric forms in solution with the same mechanism used for phospho-peptide 
substrates [68]. The lengths of the V-S and V-O bonds were similar to those observed in the 
structures of PTP and monomeric vanadate; the second vanadium atom is coordinated in a distorted 
trigonal bipyramid with two bridging oxygens. The other three oxygens bind to the NH atoms of 
Gln446 and Gln450, to a water molecule, and to the amino group of Lys447 (Fig. 4). The structure with 
divanadate is intriguing as it demonstrates that indeed two metal ions can be accommodated in the 
active site of a PTP.  
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[FIGURE 4] 
Vanadate undergoes multiple chemical reactions, such as complexation with many commonly 
employed buffers, reduction, and olation to form polyoxymetallates [69-71]. Because of this 
complex chemistry, it is important to determine the species interacting with proteins at physiological 
pH. For example, H2VO4
-, the main species at pH 7, can increase its coordination number by binding 
additional water molecules or dimerize to divanadate, tetravanadate, or species of higher nuclearity, 
in particular at higher concentrations. In order to minimize oligomerization, it is recommended to 
prepare stock solutions of vanadate > 0.1 mM at pH 10 and boil the solution [72]. Compounds with 
thiols such as glutathione and ascorbate reduce vanadium(V) to vanadium(IV) [52, 56]. The reduction 
was investigated in the cytoplasm of human erythrocytes after uptake of vanadate and advanced to 
explain the inability of exogenously added vanadate to inhibit the (Na,K)-ATPase in vivo [73]. The 
reduction of vanadate(V) to vanadium(IV) species may also be important in the presence of thiol-
based reducing agents typically employed in assays of PTPs. Whether vanadate is an oxidant for the 
catalytic cysteine in PTP1B has not been considered and/or examined, however. The best known salt 
of V(IV) is vanadyl sulphate, which contains the oxidovanadium (“vanadyl”) cation [V(IV)O]2+. This 
cation is also an inhibitor of PTP1B with a Ki value of 0.11 μM (pH 7.0, 37 
oC) [74].  It must be kept in 
mind, however, that upon dissolution of vanadyl sulphate a significant fraction of vanadium(IV) 
oxidizes immediately to vanadium(V) at neutral pH. Quite appropriately, it was discussed how an 
anion as well as a cation can be an inhibitor of phosphatases [71]. The answer lies in the speciation 
of the cation. The vanadyl cation is stable at acidic pH and the hydrated species [VO(H2O)5]
2+ with a 
square pyramidal geometry undergoes consecutive hydrolysis when the pH increases to form anionic 
species at nanomolar to submicromolar concentrations: [VO(H2O)4(OH)]
-, [(VO)2(OH)5]
-, and 
[VO(OH)3]
-. Thus, there are anionic and cationic species in equilibrium with insoluble {VO(OH)2}n and 
with [(VO)2(OH)5]
- being a prominent species at neutral pH [71]. In addition, vanadium(V) also exists 
in both cationic and anionic forms [75]. In acidic solutions, the cationic species is [V(V)O2]
+, which 
binds to proteins such as transferrin [75]. Coordination of vanadium(IV) and vanadium(V) ions with 
biological ligands is another factor of speciation in a biological matrix [70]. 
In addition to inorganic vanadate(V) and oxidovanadium(IV), many organic vanadium(V) and 
vanadium(IV) compounds were investigated as inhibitors of PTP1B owing to their potential as 
antidiabetic agents and for many other therapeutic indications (see below). Vanadium complexes 
inhibit PTP1B with IC50 values between 30 nM and about 1 µM but rarely do they show pronounced 
selectivity for a particular phosphatase [76]. The actual mechanism of inhibition remains to be 
elucidated. So far, only vanadate has been investigated in 3D structures of PTPs. The rationale for 
the significant activity in synthesizing metallodrugs as inhibitors of PTPs is based on the expectation 
that membrane permeability, compartmentalization, toxicity, and selectivity for different PTPs can 
be achieved by the organic ligand, thus overcoming the inherent poor selectivity of vanadate. 
Vanadium compounds receive a great deal of interest as antidiabetic agents and, more recently, as 
potential anticancer drugs [55, 69]. Because of their favorable properties (membrane permeability, 
stability, and potency), work focused on organic chelates of VO2+, oxidovanadium(IV). VO(acac)2 
(acac = acetylacetonate) is an uncompetitive inhibitor of PTP1B when assayed with a 
phosphotyrosine peptide that stimulates the epidermal growth factor receptor (EGFR) [77]. Likewise, 
bis-(maltolato)oxovanadium(IV) (BMOV) is a reversible inhibitor of glutathionetransferase-tagged 
PTP1B with an IC50 of 0.86±0.02 μM. In this case, the inhibition is mixed with Ki values of 1.2 and 2.1 
μM for the enzyme and the enzyme/substrate (p-nitrophenyl phosphate) complex, respectively [78]. 
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2.3.2 Tungstate 
The crystal structure of Yersinia PTP (YopH) with tungstate indicates that tungstate behaves like 
other phosphate mimetics, namely closing the WPD loop [79] (Fig. 5A). In contrast to vanadate, 
tungstate does not form a covalent intermediate. PTP1B has also been crystallized with tungstate 
[80] (Fig. 5B). Two of the tungstate oxygens form hydrogen bonds with the amide groups of Ser216, 
Ile219 and Gly220. Arg221 also coordinates with one of the tungstate oxygens. Tungstate binding to the 
catalytic site of PTP1B causes conformational changes in the enzymes: the side chains of both Cys215 
and Arg221 re-position towards the oxyanion. However, the WPD loop remains in the open 
conformation. The fact that the crystals were obtained by soaking PTP1B in the presence of high 
concentrations of tungstate together with the fact that the WPD loop is closed in the Yersinia PTP 
structure, suggests that binding of tungstate in the open conformation of PTP1B is an artifact of the 
crystallization condition.  
[FIGURE 5] 
2.3.3 Molybdate 
There are no available structures of PTP1B with molybdate. There is, however, a structure of the 
bovine low molecular weight PTP co-crystallized with molybdate [60]. In this work, the phosphatase 
was crystallized with tungstate, molybdate and vanadate and the inhibition constants of the metal 
oxyanions were measured. Vanadate was the stronger inhibitor, displaying typical tbp geometry, 
while molybdate and tungstate were weaker inhibitors (9 μM and 210 μM, respectively). Unlike 
vanadate, but similar to tungstate in PTP1B, molybdate does not form a covalent intermediate but in 
this case the enzyme is in the closed conformation (Fig. 6).  
[FIGURE 6] 
2.3.4 Nitrate 
Other oxyanions also interact with PTP1B.  No information is available on the role that nitrate (NO3
-) 
has on PTP activity.  Hence we determined its inhibition.  The IC50 value is 54 mM (unpublished data, 
K. Birla Singh). Crystal structures of PTP1B in the presence of nitrate have been solved [81]. The WPD 
loop was captured in both an open and a closed conformation (Fig. 7A, B).  Nitrate is held in place by 
non-covalent interactions: in the closed form, it forms hydrogen bonds with Arg221, Asp181, Ser216, 
Ala217, and Gly220 (Fig. 7B); in the open form, the distances to Ala217, Gly220 and Arg221 are slightly less 
and it also forms hydrogen bonds with Ile219 (Fig. 7A). The movement of the WPD loop seems to 
change only slightly the position of the oxyanion in relation to the catalytic site [81]. Nitrate was also 
crystallized in a complex with Yersinia PTP [79]. In this case, the WPD loop is in the closed 
conformation and the coordination is virtually identical to the one observed in PTP1B (Fig. 7C).  
[FIGURE 7] 
2.3.5 Arsenate 
Arsenate inhibits PTP1B with a Ki of 4.3 mM [50]. Under our experimental conditions the IC50 value is 
200 µM (unpublished data, K. Birla Singh). There is no crystal structure of PTP1B with arsenate. 
However, arsenate reductase belongs structurally to the family of PTPs and several crystal structures 
have been solved [82]. Remarkably, the protein phosphatase CD45 belonging to the PTP superfamily 
reduces arsenate [83].  
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3. Significance of PTP1B inhibition 
Both metal cations and oxyanions inhibit the activity of PTP1B. Although several metal ion 
complexes have been investigated with regard to inhibiting PTPs and shown promises as 
metallodrugs, and in the case of vanadium compounds entered clinical trials, none have developed 
into human therapeuticals. Given the inhibition of PT1PB by free metal ions, investigations of the 
interaction of metal ion complexes with PTPs need to consider the stability of the metal ion 
complexes in order to determine whether the inhibition is due to the metal ion complex itself or the 
cation dissociating from the complex. Understanding the interaction of free metal ions and/or 
oxyanions with PTP1B, therefore, is important in order to improve the design of potential 
therapeutic agents. 
Investigation of vanadate as an insulin-mimetic dates back to 1899, when it was observed that oral 
administration of Na3VO4 to diabetic patients decreased glycosuria [84]. The study did not have any 
follow up until 80 years later, when it was shown that several inorganic vanadium compounds 
affected adipocytes similar to insulin, namely stimulating glucose transport and oxidation, and 
hepatocytes, namely increasing glycogen synthesis and inhibiting gluconeogenesis [85]. Notably, this 
work was performed at a time when the search for a molecular function of vanadium in biology was 
on-going, a scientific journey that started when very high (hundreds of millimolar) concentrations of 
vanadium were found in tunicates (ascidians) [86]. While vanadium is now well established as an 
essential element in nitrogenases and haloperoxidases in some branches of life, an essential 
molecular function in humans remains unknown. Inhibition of PTP1B by vanadate provides one 
explanation of the insulin-like effects of vanadate, often referred to as “insulin-mimetic” but more 
appropriately described as insulin-enhancing or insulin sparing, though other PTP involved in the 
insulin signal transduction pathways may contribute as well [87]. Numerous studies have explored 
the various insulin-enhancing effects of vanadate and vanadium compounds both in vitro and in vivo. 
Of interest was the discovery that Na3VO4 normalized hyperglycemia in an animal model of diabetes 
[88], suggesting that vanadate or vanadium compounds could potentially be used for the treatment 
of diabetes [89]. Speciation again is an issue as vanadate and vanadium(V) compounds are thought 
to be reduced to vanadium(IV) compounds in cells and will form complexes with other metabolites. 
Moreover, in the presence of reactive species such as under conditions of peroxide signalling, there 
is the possibility of oxidation of vanadium(IV) to vanadium(V), i.e. vanadium undergoing 1-electron 
redox cycling, thus accounting for the formation of organic radicals and the toxicity of vanadium 
compounds. Amongst vanadium compounds, bis(ethylmaltolato)oxidovanadium(IV) (BEOV), showed 
encouraging results and was in clinical trials as a prodrug for the treatment of type 2 diabetes [90]. 
This vanadyl (VO2+, oxidovanadium(IV)) chelate and the corresponding acetylacetonate have been 
investigated in detail structurally and with regard to their synergism with insulin in cells [91].  Phase I 
and phase II pre-clinical trials were performed with organic vanadium compounds as antidiabetic 
drugs (while vanadyl sulphate and vanadate, owing to the fact that their toxicity was known, went 
directly into phase II clinical trials) but had to be discontinued because of renal complications [90, 
92, 93]. So far, vanadium join the failures of finding specific drugs that target PTP1B, which after 
enormous efforts were deemed “undruggable” by the pharmaceutical industry. However, PTP1B has 
received additional attention because it is a validated therapeutic target in Her2-positive breast 
cancer and inhibitors are discussed as a therapeutic approach to Rett syndrome and anxiety 
disorders [94, 95]. 
Similar to vanadate, tungstate alters glucose metabolism when added to rat hepatocytes [96]. 
Follow-up experiments confirmed that administration of tungstate, like vanadate, to diabetic rats 
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normalized glycaemia and hepatic glucose metabolism [97]. Sodium tungstate has been proposed as 
a potential therapeutic agent for type 2 diabetes and although its effects as an inhibitor of PTP1B 
have been acknowledged, the antidiabetic properties of sodium tungstate may be related to effects 
other than that of being a PTP1B inhibitor [98]. Similar conclusions were reached when the role of 
tungstate as an antiplatelet agent was investigated and the effects were thought to be due to 
inhibition of PTP1B – at least in part [99].  
Molybdate has also been widely used as a PTP inhibitor [100-102]. In contrast to vanadium and 
tungsten, molybdenum is an essential element for humans. Its function as a cofactor in enzymes is 
linked to its binding to the pterin prosthetic group. In rat hepatocytes, molybdate inhibits glycogen 
synthase and increases fructose bisphosphate, while it increases glucose uptake in rat adipocytes 
[103]. The action is likely due to an increased phosphorylation of the insulin receptor and the insulin 
receptor substrate [104]. Experiments with molybdenum supplementation have also been 
performed on diabetic rats. Molybdate decreased hyperglycemia and glycosuria, improved glucose 
tolerance, and replenished glycogen stores [105].  
It is unclear whether the concentrations at which vanadate and other oxyanions inhibit the activity 
of PTP1B occur under physiological conditions. Relatively low metal oxyanions concentrations (e.g. 
vanadate, ~1 µM) inhibit PTPs. Vanadium concentrations in human blood are 0.2-15 nM (median 50 
ng/L in 108 human subjects) [106]. Based on about 1 mg of vanadium in a 70 kg human and 
assuming a random distribution, one can calculate an average vanadium concentration of 0.3 µM 
[54]. Other (non-metal) oxyanions, such as phosphate, nitrate, borate, sulphate inhibit in the 
millimolar range, but none of the inhibition of these ions appears to be physiologically relevant in 
living cells. For example, phosphate inhibits with a Ki of 17 mM while the cellular phosphate 
concentrations are in the range of 0.5 - 5 mM.  
Zinc ions, on the other hand, are physiologically important inhibitors of enzymes [2]. Other metal 
ions, either essential metal ions such as iron(II,III) and copper(I,II) or non-essential metal ions have 
pathophysiological/toxicological effects on PTPs. In order to interpret metal ion inhibition of PTPs, an 
understanding of the cellular concentrations of total and free metal ions is necessary.    
 
3.1 Physiological metal cation concentrations 
Apart from the properties of the metal cation and its affinity for ligands, the actual concentration of 
the metal ions available for protein binding is a crucial factor in determining whether or not a 
protein indeed binds a particular metal ion in the cell. The factor determining the availability is the 
range in which metal ions are buffered in the cell. Cellular metal homeostasis is a well-controlled 
process, involving many transporter proteins as well as storage in organelles.  
In general, the affinity of a divalent metal ion for a set of ligands follows the Irving-Williams series 
[107], which ranks the metal ion complexes based on their stability in the following order: 
Mg
2+
 < Mn
2+
 < Fe
2+
 < Co
2+
 < Ni
2+
 < Cu
2+
 > Zn
2+ 
This signifies that metal ions such as Zn2+ or Cu2+ form the most stable complexes with a particular 
set of ligands. However, by increasing the total concentration of a weaker binding metal cation, the 
cell can enhance its competitiveness for a target protein if the buffering allows for an increased 
availability. 
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The cytosolic free concentrations of essential metal ions vary over many orders of magnitude and 
they are kept in defined ranges by buffering in order to avoid overlapping functions of the different 
metal ions (Table 6).  Although the concentration of some metal ions is low at steady state, there are 
instances where it increases either globally or locally. For instance, the cytosolic Ca2+ concentration 
increases in response to second messengers such as inositol trisphosphate, IP3 [108]. Zinc ion 
concentrations also increase in response to various stimuli such as high glucose concentrations, 
insulin, growth factors, and changes to a lower reducing potential [109-111].  
Table 6. Intracellular free metal ion concentrations ([Me2+]i). 
Metal Free [Me
2+
]i Reference 
Zn 600 pM - 1 nM  [112, 113] 
Fe < 5 μM [114, 115] 
Cu 1 aM [116] 
Ca 100 nM [117] 
Mg 1 mM [118, 119] 
 
3.1.1 Zinc(II) 
Zinc ions have been referred to as insulin-mimetics as incubation of cells with zinc ions results in 
glucose transport [120] and lipogenesis [121]. The insulin-mimetic effects are associated with an 
increased tyrosine phosphorylation, and  it has been suggested that these effects are due to a direct 
interaction of zinc ions with PTPs [35]. There is a large body of evidence suggesting that zinc ions are 
indeed bona fide endogenous modulators of PTPs, putting the observation of zinc ion inhibition 
observed in vitro in a physiological context. Some PTPs such as PTPRB could be inhibited at resting 
zinc ion concentrations [26], while others will need increased cytosolic zinc ion concentrations as the 
inhibition constants are above the cytosolic free zinc ion concentrations (Table 3). 
Cellular zinc ion homeostasis is tightly controlled. It is fairly well established now that the 
concentration of free zinc ions in the cytosol is in the range of a few hundred pM [112, 113]. The 
concentration of zinc ions inside intracellular organelles, however, is more controversial and 
investigations using different fluorescent probes provided very different values [122, 123]. 
Metallothionein is a major zinc ion-binding protein contributing to maintaining the cytosolic free zinc 
ion concentrations at high picomolar/low nanomolar concentrations [112, 124]. Two families of zinc 
transporters also participate in this control. Fourteen members of importers (Zip/SLC39A) and at 
least nine out of the ten members of transporters (ZnT/SLC30A) transport zinc ions into and out of 
the cell [125]. These proteins are located on the plasma membrane as well as on membranes of 
intracellular organelles. The release of zinc ions into the cytosol through some of these transporters 
results in free zinc ion concentrations that are locally higher than those under steady-state 
conditions. Stimuli such as prolonged hyperglycemia [109], EGF [111] or insulin [110] increase the 
cellular free zinc on concentration. Two pathways may be relevant for local increases of zinc ions at 
the endoplasmic reticulum (ER) where PTP1B resides. One pathway is the transport of zinc ions 
through zinc transporters (Fig. 8). Zip7 (SLC39A7) is located on the ER membrane and responsible for 
transporting zinc ions into the cytosol. Stimulation of cells with EGF in the presence of high 
intracellular Ca2+ activates casein kinase 2 (CK2) that is consequently recruited to the ER, where it 
phosphorylates Zip7 on Ser275 and Ser276 [111]. This modification causes an opening of the channel 
and increases in zinc ion concentrations in the cytosol. However, because zinc ions are buffered in 
the cytosol, the global free zinc concentration would not be expected to change. The concentration 
of zinc at the ER membrane would be high enough for PTP1B inhibition. Insulin increases cellular free 
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zinc ion concentrations.  For example, treatment of a T-cell lymphoma cell line with 5-10 μg/ml 
insulin elicits a 2-3.5-fold increase of zinc ion concentrations [110]. To rule out that the increase of 
intracellular zinc ions in these experiments was due to an influx of zinc contained in the insulin 
preparation, which often contains rather high concentrations of zinc ions, the same experiment was 
repeated after boiling the insulin sample and hence denaturing the hormone. No increase in 
fluorescence was observed with this preparation [110]. 
[FIGURE 8] 
Increasing of cellular free zinc ions can also arise from the production of reactive oxygen species 
(ROS) and oxidation of metallothioneins (MTs) (Fig. 8). Insulin binding and activation of the insulin 
receptor induces an increase of intracellular H2O2 in both hepatocytes and adipocytes [126]. ROS are 
produced from Nox4, the phagocytic NAD(P)H oxidase catalytic subunit, which is highly expressed in 
insulin-sensitive adipocytes. Expression of dominant negative forms attenuated insulin-stimulated 
H2O2 production in adipocytes while silencing of Nox4 inhibited the insulin signalling cascade [127]. 
Targets of H2O2 are PTPs, in particular PTP1B, which is reversibly inhibited, thus enhancing insulin 
signaling pathways [128] (section 3.2). A second mode of action is the reaction of H2O2 with MTs. 
Oxidation of MTs results in release of tightly bound zinc ions, which also inhibit PTP1B [129, 130]. 
Insulin stimulation therefore enhances its own signal through inhibition of PTP1B by redox and zinc 
ion signals (Fig. 8). Incubation of adipocytes in a medium containing high glucose concentrations 
resulted in enhanced H2O2 production and PTP oxidation [131]. Incubation of cells with high glucose 
concentrations also has been linked with an increase in intracellular free zinc ion concentrations 
[109], demonstrating the joint action of redox and zinc signals on modulation of PTP activity. 
However, the mode of inhibition by zinc ions suggests that modulation of PTP1B activity by either 
oxidation or zinc ions occurs at two distinct stages. PTP1B is oxidized at the resting level, 
independently of physiological stimulation and substrate binding. In contrast, zinc ions modulate 
PTP1B after physiological stimulation and substrate binding. Aside from the fact that zinc ion signals 
can be a product of oxidative signaling, zinc ion signals are specific based on affinities of zinc ions for 
coordination environments and can provide a longer lasting inhibition of PTPs [132]. 
3.1.2 Other metal ions 
The inhibition of PTP1B by metal ions other than zinc ions does not appear to be physiologically 
significant but it may have significance under conditions where tissues and cells are exposed to toxic 
metal ion concentrations [37]. 
 
3.2 Redox regulation of PTP1B 
Oxidation/reduction (redox) is a key regulatory event in PTP function. Intracellular signals resulting in 
the production of ROS increase tyrosine phosphorylation due to inhibition of PTPs [133]. ROS oxidize 
the active site cysteine (Cys215 in PTP1B) and abrogate its nucleophilic function. Oxidation is 
reversible as the sulphenic acid form of the oxidized cysteine reacts with the adjacent serine side 
chain (Ser216) to form a cyclic sulphenamide with the purpose of avoiding further oxidation and 
facilitating reduction to restore the active PTP [134] (Fig. 9). Formation of the cyclic sulphenamide is 
accompanied by conformational changes as the PTP loop with the signature motif VHCxAGxxRSG 
and Tyr46 (in PTP1B), normally buried in the structure, become more solvent-exposed.  
[FIGURE 9] 
  
19 
 
Oxidation can also lead to the formation of sulphinic or sulphonic acid derivatives of Cys215 [7, 134]. 
The oxidation to sulphonic acid is irreversible. Additional modifications are glutathionylation, 
sulphenation with hydrogen sulphide and reactions with reactive selenium compounds. The 
reduction of the oxidized cysteine depends on an interaction of the protein with thioredoxin [135, 
136]. 
 
3.3 PTP1B as a drug target 
Given the role of PTP1B in the pathogenesis of type 2 diabetes and its involvement in cancer 
signaling, immense research efforts are made to pharmacologically targeting the enzyme [137]. 
Antisense-based oligonucleotides designed to downregulate PTP1B expression and normalizing 
glycaemia and improving insulin sensitivity have entered Phase II clinical trials [138, 139]. Although 
the trial is over, the results are not yet available to the public [140].  
There are two main challenges when designing PTPs inhibitors: cell membrane permeability and 
selectivity [137]. Inhibitors for PTPs, and in particular PTP1B, include phosphate mimetics, such as 
vanadium compounds. Chelation overcomes the issues of cell membrane permeability, and a barrier 
of positive charges around the active site. Selectivity continues to be an issue as many PTPs share 
common residues in their catalytic sites.  
Since diabetes and other diseases are associated with changes in zinc status, one would assume that 
an approach targeting intracellular control of zinc is worth exploring for pharmacological 
intervention. 
4. Conclusions 
Phosphatases are the jockeys while kinases are the racehorses in cellular regulation. Phosphatases 
perform the task of regulating phosphorylation signaling and they are regulated themselves. We 
demonstrate additional principles of the regulation of PTPs, namely reversible inhibition by metal 
cations that inhibit differently from metal anions such as vanadate. Oxyanions bind to the enzymes 
in the open conformation but cations inhibit only if an oxyanion such as phosphate (or vanadate) is 
already present and new interactions for cation binding are made possible in the closed 
conformation of the protein when the catalytic aspartate moves into the active site.  
Metal cation inhibition modulates PTPs differently from established redox modulation. Metal cations 
bind when phosphate (or another oxyanion) blocks the cysteine in the phospho-intermediate, and 
thus the sulphur is no longer available for redox modification. Possibly, the combined anion/cation 
inhibition protects the enzyme from redox modification.   
Metal modulation has been ignored in virtually all discussions of the biology of PTPs. The inhibition 
of PTPs by metal ions was recognized when these enzymes were initially characterized [26]. The 
reasons for a lack of progress are that the structural chemistry of metal cation inhibition was not 
explored, and in fact could not have been explored, because it requires a particular intermediate of 
the enzyme in the reaction cycle, and that the relationship between physiological zinc ion 
concentrations and inhibition was not recognized. Oxyanion modulation alone is not important 
physiologically unless it is seen in the context of metal cation binding. There is controlled zinc ion 
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release at the ER where PTP1B resides and it is now understood that physiological concentrations of 
zinc ions are commensurate with the inhibition constants of PTPs for zinc ions.  
Transition metal ions are redox active and influence the redox state of the catalytic cysteine in PTPs. 
In contrast, zinc(II) is redox-inert in biology and cannot change the redox state of the cysteine. 
However, ROS release zinc ions from metallothionein and other protein sites and thus increase free 
zinc ion concentrations. Therefore, some of the effects of ROS on PTPs may be indirect, namely in 
providing zinc ions as a specific inhibitor of the enzymes. In as much as redox species are ER 
localized, so is zinc ion release, and specific pathways of zinc ion release support the physiological 
relevance. The physiological context of dual modulation of PTPs by metal ions and redox is likely 
another level of control of these important enzymes (Fig. 10).  
[FIGURE 10] 
The interplay of anions, cations and redox agents provides a very rich chemistry for affecting the 
active site of PTPs and consequently their biological control. On a more speculative note, the zinc 
ioin inhibition of the phosphorylated form relates the activity of the PTPs to the phosphorylation 
state of their substrates, i.e. inhibition occurs during enzymatic turnover while redox modulation 
targets the free enzyme before (or after) it has been enzymatically active. 
Metal ion interactions with PTPs extend the role of metal ions in phosphatase action and 
phosphorylation signaling. Alkaline phosphatases use a binuclear zinc site and a regulatory 
magnesium ion, acid phosphatases a binuclear iron site, and protein phosphatases such as 
calcineurin a mixed binuclear zinc/iron site. Thus, in addition to using metalloenzymes in the control 
of phosphorylation signaling, biology has availed itself to using metal ions such as zinc and calcium 
for biological regulation of phosphatases.  
It is remarkable that billions of dollars have been spent on drug design and clinical trials of inhibitors 
of PTPs without appreciating these structural and biological principles of regulation. The new 
insights provide a different perspective and may give another impetus for rational drug design and 
for inhibiting PTPs more specifically by modulating zinc metabolism in vivo. Such an approach 
appears to be attractive since the zinc and vanadium inhibition of PTP1B provides a mechanistic 
basis for the rather copious literature on the pharmacology of insulin-mimetic and anti-diabetic 
effects of zinc and vanadium complexes [141-143]. 
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Figure Legends 
 
Figure 1. Protein tyrosine phosphatases catalyse the dephosphorylation of the substrate by a ping-
pong mechanism. The enzyme initially is in a resting state with the WPD loop open (PDB id: 2CM2). 
Upon substrate (in orange) entry into the catalytic pocket, the WPD loop closes (PDB id: 1PTU, 
Michaelis complex). The enzyme goes through the first transition state (PDB id: 3I7Z) and the first 
product is released with the enzyme left in a phospho-cysteine intermediate (PDB id: 1A5Y, Q262A 
mutant). A water molecule is subsequently activated in the second transition state (PDB id: 3I80), 
before the WPD loop opens again (PDB id: 2HNQ, Michaelis complex) and the inorganic phosphate is 
released. Modified from Brandao et al, [24]. 
 
Figure 2. Docking simulation performed on different PTP1B crystal structures. (A) Closed form (PDB 
id: 3I80) and (B) phospho-cysteine intermediate (PDP id: 1A5Y).  Since the position of the zinc ion in 
the two structures differs by about 4 Å Gln266 in (A) is too far for coordination. Gln262 is not shown 
in (B) as the structure was obtained on a Gln262Ala mutant to avoid hydrolysis of the phospho-
cysteine intermediate. Protein structure is represented in pale cyan, zinc ion as pink sphere, and 
relevant amino acids as sticks [28].  
 
Figure 3. X-ray crystal structure of (A) first transition state complex between PTP1B, metavanadate, 
and the Tyr in the peptide DADEYL (PDB id: 3I7Z) and (B) second transition state complex between 
PTP1B and orthovanadate (PDB id: 3I80) [24]. Protein structure is represented in pale cyan, peptide 
DADEYL in orange, and vanadate and relevant amino acids as sticks. H-bonds are depicted as yellow 
dot lines. 
 
Figure 4. X-ray crystal structure of Yersinia enterocolitica PTP (R235C, W354F) complexed with 
divanadate (PDB id: 3F9B) [67]. Protein structure is represented in pale green, and vanadate and 
relevant amino acids as sticks. H-bonds are depicted as yellow dot lines. 
 
Figure 5. X-ray crystal structures of (A) Yersinia PTPase (R235C) (PDB id: 1YTW) [79] and (B) human 
PTP1B (PDB id: 2HNQ) complexed with tungstate [80]. Protein structures are represented in pink and 
pale cyan respectively, tungstate and relevant amino acids as sticks. H-bonds are depicted as yellow 
dot lines, distances are in Å. 
 
Figure 6. X-ray crystal structure of bovine low molecular weight PTPase complexed with molybdate 
(PDB id: 1Z13) [60]. Protein structure is represented in green, molybdate and relevant amino acids as 
sticks. H-bonds are depicted as yellow dot lines, distances are in Å. 
 
Figure 7. X-ray crystal structure of human PTP1B complexed with nitrate (PDB id: 4BJO): (A) open 
form and (B) closed form [81]. Protein structure is represented in pale cyan, and nitrate and relevant 
amino acids as sticks. H-bonds are depicted as yellow dot lines, distance are in Å. (C) X-ray crystal 
structure of Yersinia PTPase (R235C) complexed with nitrate (PDB id: 1YTN) [79]. Protein structure is 
represented in pink, nitrate and relevant amino acids as sticks. H-bonds are depicted as yellow dot 
lines, distances are in Å. 
 
Figure 8. Mechanisms involved in increasing cytosolic zinc after insulin stimulation. Insulin binding to 
its receptor induces zinc increase through the zinc transporter Zip7 located on the endoplasmic 
reticulum (ER) membrane or through other Zips located on the plasma membrane. Insulin stimulates 
the insulin receptor (IR), which triggers an increase in ROS production. Oxidation of metallothioneins 
(MT) releases the bound zinc ions. Zinc then inhibits PTP1B, hence blocking the dephosphorylation of 
the insulin receptor. The figure was made using Servier Medical Art (www.servier.com). 
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Figure 9. Redox chemistry of the active site cysteine in PTPs. 
 
Figure 10. Modulation of PTP1B by oxidation of the catalytic cysteine and zinc binding at different 
stages of the catalytic cycle. While oxidation targets the enzyme in the open conformation, zinc 
modulates the enzyme after the WPD loop has closed. Modified from Brandao et al, [24]. 
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• Modulation of phosphatase activity by metal cations and metal oxyanions  
• Zinc inhibition of protein tyrosine phosphatase 1B  
• Structural chemistry of inhibitory metal sites in proteins  
• Metal buffering in enzymatic assays  
 
